TITLE:
Advances in the Treatment of Advanced Non-Small Cell Lung Cancer
AUTHORS:
Xianshan Chen, Juncheng Guo, Min Guo
KEYWORDS:
Non-Small Cell Lung Cancer, Drugs, Targeted, Chemotherapy
JOURNAL NAME:
Advances in Lung Cancer,
Vol.9 No.2,
June
29,
2020
ABSTRACT: In recent years, the incidence of lung
adenocarcinoma has been increasing, and now
it has become the largest type of non-small cell lung cancer (NSCLC).
Currently, treatment of advanced NSCLC consists of several modalities: systemic
chemotherapy, local radiation therapy, and targeted therapy (including most recently
immunotherapy). In the past decade, the discovery of new molecular subtypes, the search for tumor driver gene
mutations, the development of targeted
molecular targeted drugs, or targeted therapy to suppress tumor angiogenesis
and regulate tumor immune response have been the main directions of NSCLC research and clinical diagnosis and
treatment. At present, platinum-based chemotherapy is widely used in NSCLC
patients clinically. Platinum-based chemotherapy drugs can effectively
prolong the survival time of patients and improve their quality of life, but
the incidence of adverse reactions is still high. Therefore, it is necessary to
find a drug that can improve the efficacy of patients and reduce the adverse
reactions of platinum chemotherapy drugs to NSCLC patients.